Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study

AbstractEarly results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement in event-free (EFS) and relapse-free survival (RFS). In order to describe second-line treatments and their implications on overall survival (OS), we performed a study after a median follow-up time of 78 months. Newly diagnosed fit AML patients aged ≤60 years received sorafenib (n = 134) or placebo (n = 133) in addition to standard chemotherapy and as maintenance treatment. The 5-year EFS was 41 versus 27% (HR 0.68; p = 0.011) and 5-year RFS was 53 versus 36% (HR 0.64; p = 0.035). Allogeneic stem cell transplantation (allo SCT) was performed in 88% of the relapsed patients. Four years after salvage allo SCT, the cumulative incidence of relapse was 54 versus 35%, and OS was 32 versus 50%. The 5-year OS from randomization in all study patients was 61 versus 53% (HR 0.82; p = 0.282). In conclusion, the addition of sorafenib to chemotherapy led to a significant prolongation of EFS and RFS. Although the OS benefit did not reach statistical significance, these results confirm the antileukaemic activity of sorafenib.

Download Full-text

Adalimumab-induced acute myeloid leukaemia in a patient with Crohn’s disease

BMJ Case Reports ◽

10.1136/bcr-2018-225680 ◽

2019 ◽

Vol 12 (2) ◽

pp. bcr-2018-225680 ◽

Cited By ~ 1

Author(s):

Talal Alzahrani ◽

Abdulelah Nuqali ◽

Nejat Naser ◽

Amar R Jariwala

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Increased Risk ◽

Binding Factor ◽

Core Binding Factor Beta ◽

Acute Myeloid

We present a patient with Crohn’s disease under treatment with adalimumab who developed acute myeloid leukaemia (AML) with core-binding factor beta gene rearrangement. This case report emphasises the importance of long-term close follow-up of patients receiving adalimumab because of the increased risk of developing AML and other malignancies.

Download Full-text

Treatment intensification with FLAG‐Ida may improve disease control in younger patients with secondary acute myeloid leukaemia: long‐term follow up of the MRC AML15 trial

British Journal of Haematology ◽

10.1111/bjh.17974 ◽

2021 ◽

Author(s):

Nigel Russell ◽

Robert Hills ◽

Lars Kjeldsen ◽

Mike Dennis ◽

Alan Burnett

Keyword(s):

Acute Myeloid Leukaemia ◽

Disease Control ◽

Myeloid Leukaemia ◽

Treatment Intensification ◽

Younger Patients ◽

Long Term Follow Up ◽

Improve Disease Control ◽

Acute Myeloid

Download Full-text

Radioimmunotherapy for treatment of acute myeloid leukaemia and myelodysplastic syndrome

Nuklearmedizin ◽

10.1055/s-0038-1625714 ◽

2005 ◽

Vol 44 (03) ◽

pp. 107-117

Author(s):

R. G. Meyer ◽

W. Herr ◽

A. Helisch ◽

P. Bartenstein ◽

I. Buchmann

Keyword(s):

Acute Myeloid Leukaemia ◽

Myeloid Leukaemia ◽

Primary Tumour ◽

The Other ◽

Haematopoietic Stem Cell ◽

Other Hand ◽

Primary Reduction ◽

The One ◽

Acute Myeloid

SummaryThe prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term diseasefree survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT.This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.

Download Full-text

World Health Organization Sub-Types, Initial Treatment Outcome and Prognostic Study of Unselected Adult Patients with Acute Myeloid Leukaemia in Shanghai: An Analysis of 623 Cases

Journal of International Medical Research ◽

10.1177/147323000903700426 ◽

2009 ◽

Vol 37 (4) ◽

pp. 1191-1201 ◽

Cited By ~ 4

Author(s):

Y Ma ◽

X Wang ◽

X Xu ◽

G Lin

Keyword(s):

Prognostic Factor ◽

Acute Myeloid Leukaemia ◽

World Health Organization ◽

Myeloid Leukaemia ◽

Treatment Effect ◽

Developed Countries ◽

World Health ◽

Health Organization ◽

Acute Myeloid

This study investigated the complete remission (CR) rate and survival of 623 newly diagnosed patients with acute myeloid leukaemia (AML) in Shanghai, China, classified according to World Health Organization and French–American–British criteria, and compared the differences in treatment effect with those reported in developed countries and those reported in Shanghai from 1984 to 1994. Total CR rate was 66.5%, median survival was 18 months and estimated survival at 3 years was 30.8%. The 3-year relapse rate was 55.1%. These data showed that the CR rate was similar to that achieved in studies from developed countries, but long-term survival was worse. The CR rate and survival were increased markedly compared with data previously collected in Shanghai (1984-1994). Induction chemotherapeutic regimens based on idarubicin, daunorubicin or homoharringtonine all had similar CR rates and survivals. Karyotype was the most important prognostic factor. Multilineage dysplasia in de novo AML was not an independent prognostic factor. Improvement in the long-term treatment effect in China is an important challenge for the future.

Download Full-text